Navigation Links
Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
Date:7/23/2008

se in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule called Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third pa
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
8. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
11. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , October 22, 2014 Investor-Edge ... Inc. (NASDAQ: FOLD ), Progenics Pharmaceuticals Inc. ... THLD ), Idera Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... 21, 2014, the NASDAQ Composite ended at 4,419.48, up ...
(Date:10/22/2014)... VERNE, Calif. , Oct. 22, 2014 /PRNewswire/ ... readiness products, has developed APLS ® Body ... that minimizes the spread of bacteria and virus ... APLS Body Guard Bio features a rugged, ... finished edges that create a leak-proof inner chamber ...
(Date:10/22/2014)... JERUSALEM , October 22, 2014 ... http://www.oramed.com ), a clinical-stage pharmaceutical company focused ... today reported positive top-line clinical results from its ... proprietary oral insulin capsules, to treat type 1 ... United States under a U.S. Food ...
Breaking Medicine Technology:Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4
... PRO-DEX, INC. (Nasdaq: PDEX ) invites investors and ... fiscal 2011 fourth quarter and full-year financial results. ... the internet on Wednesday, September 14, 2011 at 4:30 p.m. ... by visiting the Company,s website at www.pro-dex.com and ...
... (NASDAQ: PCYC ), a biopharmaceutical company focused ... the treatment of cancer and immune mediated diseases, today ... fourth fiscal quarter and fiscal year ended June 30, ... 12, 2011.  The company will conduct a conference call ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2011 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast 2Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call 2
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter ... among young adult men may lead to increased blood pressure, ... cause a similar rise in blood pressure for young adult ... when young adult women drank lightly or moderately, their risk ... found. "This finding parallels studies in older adult men ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... who was diagnosed with Ebola while working for NBC News ... can leave the special isolation unit at Nebraska Medical Center in ... the hospital said Tuesday. A blood test confirmed by the ... 33, can head home to Providence, R.I., NBC News ...
(Date:10/20/2014)... MA (PRWEB) October 20, 2014 ... sponsoring a booth at the American Foundation for Suicide ... 25th. The AFSP is a not-for-profit organization that hosts ... Net proceeds from these events are used to help ... but education and personal relationships as well. , ...
(Date:10/20/2014)... October 20, 2014 hc1.com today ... secure cloud solution that enables healthcare organizations of ... ultimate healthcare-specific customer relationship management (“CRM”) solution. , ... unique needs of the healthcare industry, the hc1 ... providers and patients by combining healthcare CRM, HIPAA-compliant ...
Breaking Medicine News(10 mins):Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2
... , GAITHERSBURG, Md., Sept. 16 On September ... notice from The NASDAQ Stock Market stating that the minimum bid ... for 30 consecutive business days and that the Company was therefore ... no effect at this time on the listing of the Company,s ...
... offsets deficits of poverty, study finds , WEDNESDAY, Sept. 16 ... inhibit a child,s intellectual development. But now researchers have ... , High-quality day care for the youngest poor kids may ... them the foundation for good school skills, at least up ...
... , , Prostate ... , DENVER, Sept. 16 This September, the Prostate ... take lifesaving measures. In just 10 minutes, the same amount ... screened for prostate cancer, the second leading cause of death among ...
... , FAIRFIELD, Conn., Sept. 16 Autism ... free services available at http://www.AutismSupportNetwork.com. Listed as one of ... ASN connects families and individuals touched by autism spectrum disorder ... as a resource guide for treatments, strategies and therapies. ...
... , , , , ... Sam Muslin, DDS, MAGD, has been awarded LA,s Best Award (tm) ... long been recognized for his pioneering work in cosmetic dentistry and ... procedure that combines the ultimate in dental technologies to achieve a ...
... , , NEW YORK, Sept. ... and disabling conditions such as cardiovascular disease, cancer, diabetes and ... -- smoking, poor dietary habits, physical inactivity and poor hygiene. ... are seldom, if ever, factored into the fractious debate about ...
Cached Medicine News:Health News:GenVec Receives NASDAQ Notice of Minimum Bid Price Non-Compliance 2Health News:GenVec Receives NASDAQ Notice of Minimum Bid Price Non-Compliance 3Health News:Better Day Care, Smarter Kids? 2Health News:Better Day Care, Smarter Kids? 3Health News:Better Day Care, Smarter Kids? 4Health News:Free Screenings During Prostate Cancer Awareness Week 2Health News:Free Screenings During Prostate Cancer Awareness Week 3Health News:Autism Support Network Launches Enhanced Features, Adds Thousands of New Members Globally 2Health News:Los Angeles Dentist Dr. Sam Muslin Receives LA's Best Award 2009 2Health News:Los Angeles Dentist Dr. Sam Muslin Receives LA's Best Award 2009 3Health News:Los Angeles Dentist Dr. Sam Muslin Receives LA's Best Award 2009 4Health News:Los Angeles Dentist Dr. Sam Muslin Receives LA's Best Award 2009 5Health News:Los Angeles Dentist Dr. Sam Muslin Receives LA's Best Award 2009 6Health News:Los Angeles Dentist Dr. Sam Muslin Receives LA's Best Award 2009 7Health News:The Sickness Crisis: America Would Save Over $700 Billion Annually Through Prevention and Health Promotion 2Health News:The Sickness Crisis: America Would Save Over $700 Billion Annually Through Prevention and Health Promotion 3
This storage freezer, which is based on our premium freezer line, maintain red cells safely below regulatory standards at -86C (-123F). Recorder is standard for model 8627. Model 8627 is UL Listed, C...
... the precise requirements of blood banking ... Bank Equipment meets American Association of ... Cross (ANRC) and U.S. Food & ... freezers, and platelet incubators feature alarm ...
... Designed for the precise requirements ... Thermo Forma Blood Bank Equipment meets ... American National Red Cross (ANRC) and ... standards. Refrigerators, storage freezers, and platelet ...
... This refrigerator is specially ... of blood in standard ... Australian Standard AS3864 1997. ... air-cooled utilising CFC Free ...
Medicine Products: